Tobacco.org

Abbott: No Lung-Cancer Signals In Inhaled-Insulin Trials 

Abbott Laboratories (ABT) has seen "no signals of lung cancer" in patient trials of its experimental inhaled insulin, a company spokesman said Thursday.

Abbott's disclosure comes a day after Pfizer Inc. (PFE) warned that a small number of users of its inhaled insulin, Exubera, developed lung cancer, though it wasn't able to determine whether Exubera was the cause. Pfizer decided last year to stop marketing Exubera due to disappointing market performance since it was approved in 2006; the company is working with doctors to switch patients from Exubera to other therapies.

Jump to full article »